| Serge Saxonov
Ben Hindson (President & CSO)
10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.
10x Genomics Wikipedia
10x Genomics was founded in 2012 by Serge Saxonov and Ben Hindson, who previously worked at Quantalife. The company raised $110 million in equity through two rounds of investment in 2015 and 2016. 10x Genomics made its public début at the JP Morgan Healthcare Conference in San Francisco in 2015. In November 2016, 10x Genomics was identified as one of the key players in the next generation sequencing (NGS) global market.
The 10x platform uses a method based on emulsion PCR in order to produce "synthetic" long reads. The 10x GemCode partitions arbitrarily large DNA fragments into micelles, along with an adapter molecule and a barcode sequence. Within each micelle, the gel bead dissolves, before smaller fragments of DNA are amplified from the large fragment. Each of the smaller fragments retain the barcode sequence which is used to identify its parent micelle. After amplification, the emulsion is broken and the DNA pooled, where it undergoes a standard library. preparation. After DNA sequencing, the reads are aligned and linked to form a series of fragments covering around 50kb. In contrast to the Illumina synthetic long-read platform, this approach does not yield full coverage of a DNA fragment. Instead, the reads from a single micelle are dispersed across the original fragment; read coverage arises through the process being applied to very large numbers of micelles.
The original 10x Genomics sequencing platform, the GemCode, was officially launched in February 2015. In February 2016, 10x Genomics announced the launch of its successor, the Chromium.